Trial Comparing Treatment With Tiotropium Inhalation Capsules to Combivent® Inhalation Aerosol in COPD Patients.
Public ClinicalTrials.gov record NCT00388882. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-blind, Double-dummy, Parallel Group Trial Comparing 12 Weeks Treatment With Tiotropium Inhalation Capsules 18 mcg Via the HandiHaler® Once Daily to Combivent® Inhalation Aerosol CFC MDI 2 Actuations q.i.d. in COPD Patients Currently Prescribed Combivent® Inhalation Aerosol CFC MDI
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The objective of this study is to evaluate the efficacy and safety of 12 weeks treatment with tiotro pium HandiHaler® 18 mcg daily compared to Combivent® MDI CFC Inhalation Aerosol 2 actuations qid in COPD patients currently prescribed Combivent® MDI.
Study identification
- NCT ID
- NCT00388882
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 4
- Enrollment
- 327 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 40 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 4, 2006 (Actual)
- Primary completion
- Oct 8, 2007 (Actual)
- Completion
- Not listed
- Last update posted
- Dec 1, 2023
Started 2006
United States locations
- U.S. sites
- 10
- U.S. states
- 7
- U.S. cities
- 10
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| 205.346.107 Boehringer Ingelheim Investigational Site | Phoenix | Arizona | — | — |
| 205.346.104 Boehringer Ingelheim Investigational Site | Lakewood | California | — | — |
| 205.346.108 Boehringer Ingelheim Investigational Site | Sepulveda | California | — | — |
| 205.346.101 Boehringer Ingelheim Investigational Site | Torrance | California | — | — |
| 205.346.106 Boehringer Ingelheim Investigational Site | Wheat Ridge | Colorado | — | — |
| 205.346.102 Boehringer Ingelheim Investigational Site | Coeur d'Alene | Idaho | — | — |
| 205.346.109 Boehringer Ingelheim Investigational Site | Shreveport | Louisiana | — | — |
| 205.346.110 Boehringer Ingelheim Investigational Site | Philadelphia | Pennsylvania | — | — |
| 205.346.105 Boehringer Ingelheim Investigational Site | Charleston | South Carolina | — | — |
| 205.346.103 Boehringer Ingelheim Investigational Site | Spartanburg | South Carolina | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 30 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00388882, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 1, 2023 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00388882 live on ClinicalTrials.gov.